

Please summarise the concall in a simple language which a ten year old can understand. Also please specifically point out the expectations or forecasts of the management. Also, if any apprehensions were expressed by the participants.

The investor meeting on June 4, 2026, focused on Wockhardt's shift from surviving financial trouble to becoming a leader in global medical innovation, particularly with their new "super-medicine" for bad bacteria.

A Simple Summary

Imagine Wockhardt as a team of scientists who spent 25 years working on a special mission to create a powerful new medicine called **Zaynich**. This medicine is like a superhero that can defeat "bad guy" germs (bacteria) that other medicines are too weak to stop. Wockhardt is also a big helper for people with "sugar sickness" (diabetes) by making lots of medicine to keep them healthy. After some tough years where they had to be very careful with their money, the company is now growing fast and is ready to share its new medicines with the whole world, starting with India and America.

Management's Expectations and Forecasts

The leaders of the company shared several big goals for the future:

- **Zaynich Sales:** They expect Zaynich to eventually reach **\$1.5 billion to \$2 billion in sales every year** globally.
- **Growth Curve:** They believe the company's growth will look like a "**hockey stick**," meaning it will start with a slow increase for the first 12 to 18 months and then shoot up very quickly.
- **Diabetes Business:** Management plans to **double their diabetes medicine business** within the next two to three years and double their making-capacity in about one year.
- **Making Money (Breakeven):** While they might spend a lot of money to start selling Zaynich, they expect that specific part of the business to stop losing money and start "breaking even" within **12 to 18 months**.

- **Future Spending (Capex):** They plan to spend between **INR 200 crores to INR 300 crores** over the next three years, mostly to build better facilities for their biological medicines.
- **Market Share:** They aim to capture **20% to 25%** of the market for resistant infections worldwide.
- **New Products:** They are preparing to file for **Foviscu** in the next few months and expect another product, **Odrate**, to be ready in about four years.

Apprehensions and Worries from Participants

The people who invest in the company (participants) asked several tough questions and expressed some concerns:

- **Execution Risks:** Investors were worried about how hard it would be to build an entirely new way of selling "innovative" drugs, which is much more complicated than selling regular "generic" medicines.
- **Short-Term Losses:** Some participants expressed concern (a "worried look") when they heard the Zaynich launch might cause a small financial loss in the first year or so.
- **Competition:** There were questions about how Zaynich would beat a competing medicine called **cefiderocol**, which is already being sold by another company.
- **China Strategy:** A participant asked why the company hadn't made more progress in China, and management admitted that finishing their study there would have delayed their overall approval by over a year.
- **Past Performance:** One investor pointed out that people had almost "forgotten about this company" before its recent comeback and asked what had gone wrong in the past.

- **Hospitals:** A question was asked about why Wockhardt's hospitals had been losing money for many years before recently becoming profitable.